NEUMOLOGÍA PEDIÁTRICA

Neumol Pediatr 2020; 15 (3): 381 - 401 C o n t e n i d o d i s p o n i b l e e n h t t p : / / www. n e umo l o g i a - p e d i a t r i c a . cl 399 Consenso chileno SOCHINEP-SER para el diagnóstico y tratamiento del asma en el escolar CA Jr, Kerley CP, et al. Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data. Lancet Respir Med 2017; 5: 881-90. 37. Bousquet J, Mantzouranis E, Cruz AA, Aït-Khaled N, Baena-Cagnani CE, Bleecker ER, at al. Uniform Definition of Asthma Severity, Control, and Exacerbations: Document Presented for the World Health Organization Consultation on Severe Asthma. Allergy Clin Immunol 2010; 126: 926- 38. 38. Bracken M. Fleming L, Hall P, Van Stiphout N, Bossley C, Biggart E, et al. The importance of nurse-led home visits in the assessment of children with problematic asthma. Arch Dis Child 2009; 94: 780–4. 39. Papi A, Brightling C, Pedersen S, Reddel H. Asthma. Lancet 2018; 391: 783-800. 40. Szefler S, Chipps B. Challenges in the treatments of asthma in children and adolescents. Ann Allergy Asthma Immunol 2018; 120: 382-8. 41. Herrera AM, Abara S, Alvarez C, Astudillo C, Corrales R, Chala E, et al. Consenso chileno SER – SOCHINEP para el manejo del asma severo en el niño. Rev Chil Enferm Respir 2016; 32: 100-112. 42. Lemanske RF, Mauger DT, Sorkness CA, Pharm D, Jackson DJ, Boehmer SJ, et al. Step-up Therapy for Children with Uncontrolled Asthma While Receiving Inhaled Corticosteroids. N Engl J Med 2010; 362: 975– 985. 43. Rodrigo G, Neffen H. Efficacy and safety of tiotropium in school-age children with moderate to severe symtomatic asthma: A sistematic review. Pediatr Allergy Immunol 2017; 28: 573-8. 44. Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, el al. A Cohort Analysis of Excess Mortality in Asthma and the Use of Inhaled- B Agonists. Am J Respir Crit Care Med. 1994; 149: 604-10. 45. Abramson MJ, Bailey MJ, Couper FJ, Driver JS, Drummer OH, Forbes AB, et al. Are asthma medications and management related to deaths from asthma? Am J Respir Crit Care Med. 2001; 163:12-8. 46. Stanford RH, Shah MB, D'Souza AO, Dhamane AD, Schatz M. Short-acting β -agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012; 109: 403-7. 47. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax. 2002; 57: 880-4. 48. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low- dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000; 343: 332-6. 49. Sobieraj DM, Weeda ER, Nguyen E, Coleman CI, White CM, Lazarus SC, et al. Association of Inhaled Corticosteroids and Long-Acting β -Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta- analysis. JAMA. 2018; 319: 1485-96. 50. O’Byrne PM, FitzGerald M, Bateman E, Barnes PJ, Zhong N, Keen C, et al. Inhaled Combined Budesonide– Formoterol as Needed in Mild Asthma. N Engl J Med. 2018; 378: 1865-76. 51. Bateman ED, Reddel HK, O’Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma. N Engl J Med. 2018; 378: 1877-87. 52. McGhee S. Biologics in pediatric lung disease. Curr Opin Pediatr 2018; 30: 366-71. 53. Herrera AM, Hernández J, Perillán JA, Lezana V, Alvarez C, Marinovic MA, et al. Tratamiento del asma severo con Omalizumab: experiencia pediátrica en Chile y revisión de la literature. Rev Chil Enferm Respir 2016; 32: 160-8. 54. Jolliffe D, Griffiths C, Camargo C, Kerley C, Jensen M, Mauger D, et al. Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta- analysis of individual participant data. Lancet Respir Med 2017; 5: 881-90. 55. Dinakar C, Chipps B. Clinical tools to assess asthma control in children. Pediatrics 2017; 139 :e20163438. doi: https://doi.org/10.1542/peds.2016-3438 56. Maitra A. Severe asthma: challenges and pitfalls in management. Indian J Pediatr 2018; 85: 763-72. 57. ush A. Asthma: What’s new, and what should be old but is not! Pediatr Respirol Crit Care Med 2017;1:2-10. 58. FitzGerald JM. Targeting lung attacks. Thorax 2011;66:365-6.
 59. Saglani S, Fleming L, Sonnappa S, Bush A. Advances in the aetiology, management, and prevention of acute asthma attacks in children. Lancet Child Adolesc Health 2019; 3:354-64. 60. Dondi A, Calamelli E, Piccinno V, Ricci G, Corsini I, Biagi C, et al, Acute Asthma in the Pediatric Emergency Department: Infections Are the Main Triggers of Exacerbations. BioMed Res Int 2017; 2017: 9687061. doi: 10.1155/2017/9687061 61. Merckx J, Ducharme FM, Martineau C, Zennek R, Gravel J, Chalut D, et al. Respiratory viruses and treatment failure in children with asthma exacerbation. Pediatrics 2018; 142: e20174105. doi: 10.1542/peds.2017-4105. 62. Bizzintino J, Lee WM, Laing IA, Vang F, Pappas T, Zhang G, et al. Association between human rhinovirus C and severity of acute asthma in children. Eur Respir J 2011; 37: 1037-42. 63. Looi K, Buckley AG, Rigby PJ, Garratt LW, Iosifidis T, Zosky GR, et al. Effects of human rhinovirus on epithelial barrier integrity and function in children with asthma. Clin Exp Allergy 2018; 48: 513–24. 64. Bonnelykke K, Coleman AT, Evans MD, Thorsen J, Waage J, Vissing NH, et al. Cadherin-related Family Member 3 Genetics and Rhinovirus C Respiratory Illnesses. Am J Respir Crit Care Med 2018; 197: 589-94. 65. Basnet S, Boshkov YA, Brockman-Schneider RA, Kuipers I. Aesif SW, Jackson DJ, et al. CDHR3 Asthma-Risk Genotype Affects Susceptibility of Airway Epithelium to Rhinovirus C Infections. Am J Respir Cell Mol Biol. 2019; 61: 450-8. 66. Kloepfer KM, Lee WM, Pappas TE, Kang TJ, Vrtis RF, Evans MD, et al. Detection of pathogenic bacteria